Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04519853
Other study ID # P00034904
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 25, 2021
Est. completion date July 1, 2023

Study information

Verified date August 2023
Source Boston Children's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot study will evaluate the safety and tolerability of a low glycemic load dietary intervention in adult patients with cystic fibrosis (CF) in a rigorous feeding study. Specific emphasis will be placed on changes in weight, body composition, and glycemic measures obtained via continuous glucose monitor (CGM) usage.


Description:

Non-pulmonary complications of cystic fibrosis (CF) are becoming increasingly prevalent with the changing landscape of CF care. CF related diabetes mellitus (CFRD) and CF related gastrointestinal (GI) complications have significant effects on morbidity and mortality. Treatment options are limited to insulin therapy for CFRD and symptom control for most GI complications. BMI is a well-established marker of morbidity and mortality in patients with CF. Many patients consume a high carbohydrate intake to meet their increase caloric needs, potentially leading to complications including post-prandial hyperglycemia, increased inflammation, and abnormal GI motility. Dietary recommendations for children and adults with CF are limited and based entirely on consensus and expert opinion. As patients with CF live longer with highly effective modulator therapy, it is important to understand the effects of dietary composition on short and long-term endocrine, GI, and pulmonary outcomes. The investigators will conduct a prospective, open-label pilot study in adults with CF and impaired glucose tolerance or indeterminate glycemia to establish the safety and tolerability of a low glycemic load (LGL) diet. Subjects will initially follow their standard diet for a 2-week run-in period, then transition to a LGL diet provided by a food delivery service for the remaining 8 weeks. The investigators will also investigate potential short-term outcomes of dietary carbohydrate manipulation, including glycemic variability measured by continuous glucose monitor (CGM), body composition via DXA, GI symptoms, and quality of life measures. The investigators hypothesize that a diet lower in carbohydrate content will be safe, tolerable, and associated with weight maintenance or gain, and that a LGL diet will result in decreased glycemic variability via CGM, improved GI symptoms, increased lean to fat mass ratio, and improved quality of life measures over an 8-week period.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date July 1, 2023
Est. primary completion date July 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Diagnosis of CF 2. Diagnosis of pancreatic insufficiency, requiring pancreatic enzyme replacement 3. Oral glucose tolerance test within the past three years showing impaired glucose tolerance (2-hour glucose =140 mg/dL) or indeterminate glycemia (1-hour glucose =200), HbA1c 5.7-6.4% in the past one year, and/or or documented random glucose =200 in the past one year 4. BMI 21-25 kg/m2 5. 18 years and above Exclusion Criteria: 1. Current use of insulin 2. Most recent HbA1c =6.5% 3. History of solid organ transplant or currently listed for solid organ transplant 4. FEV1 <50% predicted on most recent pulmonary function testing 5. Currently receiving enteral nutrition support 6. Current or anticipated pregnancy in the next 1 year 7. Hospitalization for CF exacerbation within 1 month of enrollment 8. Started or stopped treatment with Trikafta or other CFTR modulator within 3 months of enrollment 9. Currently adhering to a low glycemic index or other carbohydrate restricted diet

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Low Glycemic Load Diet
Food delivery service will provide a low glycemic load diet for 8 weeks

Locations

Country Name City State
United States Boston Children's Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Boston Children's Hospital

Country where clinical trial is conducted

United States, 

References & Publications (5)

Balzer BW, Graham CL, Craig ME, Selvadurai H, Donaghue KC, Brand-Miller JC, Steinbeck KS. Low glycaemic index dietary interventions in youth with cystic fibrosis: a systematic review and discussion of the clinical implications. Nutrients. 2012 Apr;4(4):286-96. doi: 10.3390/nu4040286. Epub 2012 Apr 18. — View Citation

Brennan AL, Gyi KM, Wood DM, Johnson J, Holliman R, Baines DL, Philips BJ, Geddes DM, Hodson ME, Baker EH. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros. 2007 Apr;6(2):101-9. doi: 10.1016/j.jcf.2006.03.009. Epub 2006 Jul 17. — View Citation

Gabel ME, Galante GJ, Freedman SD. Gastrointestinal and Hepatobiliary Disease in Cystic Fibrosis. Semin Respir Crit Care Med. 2019 Dec;40(6):825-841. doi: 10.1055/s-0039-1697591. Epub 2019 Oct 28. — View Citation

Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B; CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010 Dec;33(12):2697-708. doi: 10.2337/dc10-1768. No abstract available. — View Citation

Prentice BJ, Ooi CY, Strachan RE, Hameed S, Ebrahimkhani S, Waters SA, Verge CF, Widger J. Early glucose abnormalities are associated with pulmonary inflammation in young children with cystic fibrosis. J Cyst Fibros. 2019 Nov;18(6):869-873. doi: 10.1016/j.jcf.2019.03.010. Epub 2019 Apr 26. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in weight from baseline and 10 weeks Anthropometric measure Baseline and 10 weeks
Primary Change in percent time <54 mg/dL Continuous glucose monitoring Baseline and 10 weeks
Primary Patient reported tolerability of dietary intervention, Likert scale Single Likert scale question of overall diet tolerability, ranging from 1 (intolerable) to 10 (completely tolerable) Single measurement at 10 weeks after diet completion
Secondary Change in percent time >140 mg/dL Continuous glucose monitoring Baseline to 10 weeks
Secondary Change in CGM average glucose Continuous glucose monitoring Baseline to 10 weeks
Secondary Change in CGM glucose management indicator (GMI) Continuous glucose monitoring Baseline to 10 weeks
Secondary Change in CGM standard deviation (SD) Continuous glucose monitoring Baseline to 10 weeks
Secondary Change in CGM coefficient of variation (CV) Continuous glucose monitoring Baseline to 10 weeks
Secondary Change in percent time less than 50 mg/dL on CGM Continuous glucose monitoring Baseline to 10 weeks
Secondary Change in percent time less than 70 mg/dL on CGM Continuous glucose monitoring Baseline to 10 weeks
Secondary Change in percent time 70-180 mg/dL on CGM Continuous glucose monitoring Baseline to 10 weeks
Secondary Change in percent time greater than 180 mg/dL on CGM Continuous glucose monitoring Baseline to 10 weeks
Secondary Change in percent time greater than >250 mg/dL on CGM Continuous glucose monitoring Baseline to 10 weeks
Secondary Number of episodes of symptomatic hypoglycemia Survey Baseline and 10 weeks
Secondary Change in lean and fat mass DXA body composition measures Baseline and 10 weeks
Secondary Change in Patient Assessment of Constipation (PAC) questionnaire score Likert scale questionnaire with 12 items, each item scored 0-4, total score ranging from 0-48 with higher scores related to worse outcomes Baseline and 10 weeks
Secondary Change in Patient Assessment of Gastrointestinal Symptom (PAGI-SYM) questionnaire score Likert scale questionnaire with 20 items, each item scored 0-5, total score ranging from 0-100 with higher scores related to worse outcomes Baseline and 10 weeks
Secondary Change in Modified Activity Questionnaire (MAQ) score Questionnaire, units of total hours of exercise over past 12 months, no min or max scores, higher value related to better outcome Baseline and 10 weeks
Secondary Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) score Likert scale questionnaire, 50 items, each scored 0-4, total score ranging from 0-100 with higher value reflecting better outcome Baseline and 10 weeks
Secondary Change in erythrocyte sedimentation rate (ESR) Laboratory test, measured in mm/hr Baseline and 10 weeks
Secondary Change in c-reactive protein (CRP) Laboratory test, measured in mg/L Baseline and 10 weeks
Secondary Change in intestinal fatty acid binding protein (I-FABP) Laboratory test, measured in ng/mL Baseline and 10 weeks
See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A